459 related articles for article (PubMed ID: 24561173)
21. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).
Falkenstein IA; Cheng L; Freeman WR
Retina; 2007 Oct; 27(8):1044-7. PubMed ID: 18040242
[TBL] [Abstract][Full Text] [Related]
22. [Intraocular pressure and ocular blood flow features intravitreal infection of anti-vascular endothelial growth factor agents].
Mamikonian VR; Galoian NS; Budzinskaia MV; Kazarian ÉÉ; Sdobnikova SV; Shmeleva-Demir OA; Rafaeian AA; Ryzhkova EG
Vestn Oftalmol; 2014; 130(5):16-21. PubMed ID: 25711057
[TBL] [Abstract][Full Text] [Related]
23. Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD.
Moraru A; Pînzaru G; Moţoc A; Costin D; Brănişteanu D
Rom J Ophthalmol; 2017; 61(3):207-211. PubMed ID: 29450400
[No Abstract] [Full Text] [Related]
24. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
Freund KB; Hoang QV; Saroj N; Thompson D
Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
[TBL] [Abstract][Full Text] [Related]
25. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
[TBL] [Abstract][Full Text] [Related]
26. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.
Rothman AL; Beca FA; Tijerina JD; Schuman DM; Parrish RK; Vanner EA; Liu KC
Ophthalmol Glaucoma; 2024; 7(3):260-270. PubMed ID: 38266962
[TBL] [Abstract][Full Text] [Related]
27. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
28. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
Nariani A; Williams B; Hariprasad SM
Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
[TBL] [Abstract][Full Text] [Related]
29. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
30. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K
Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
[TBL] [Abstract][Full Text] [Related]
32. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
33. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents.
Pershing S; Bakri SJ; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(5):460-4. PubMed ID: 24044708
[TBL] [Abstract][Full Text] [Related]
34. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
[TBL] [Abstract][Full Text] [Related]
35. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
36. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
37. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
[TBL] [Abstract][Full Text] [Related]
38. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?
Kim D; Nam WH; Kim HK; Yi K
J Glaucoma; 2014 Sep; 23(7):446-8. PubMed ID: 23632401
[TBL] [Abstract][Full Text] [Related]
39. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment.
Bloch SB; la Cour M; Sander B; Hansen LK; Fuchs J; Lund-Andersen H; Larsen M
Acta Ophthalmol; 2013 Feb; 91(1):42-7. PubMed ID: 22008284
[TBL] [Abstract][Full Text] [Related]
40. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
